Lunsumio (mosunetuzumab-axgb) Patient Assistance Program
Don’t let the high cost of brand CD20xCD3 bispecific antibody disrupt your relapsed/refractory follicular lymphoma treatment. We help eligible patients access Lunsumio (mosunetuzumab-axgb intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Lunsumio (mosunetuzumab-axgb) is FDA-approved for adults with relapsed or refractory follicular lymphoma (FL) after two or more prior systemic therapies. CD20 × CD3 bispecific antibody — engages T cells to redirect cytotoxic activity against CD20-expressing B-cell lymphoma cells. Off-the-shelf alternative to CAR-T cell therapy with shorter treatment duration (8 cycles for responders).
- Without assistance, Lunsumio costs commonly run approximately $12,000–$16,000 per dose (varies by cycle and step-up dosing schedule).
- Through AffordMyPrescriptions, qualifying patients can access Lunsumio for a flat $69.95 per month.
- Other FL therapies: rituximab (Rituxan biosimilars now widely available — Truxima, Ruxience, Riabni) ± chemotherapy (bendamustine, CHOP backbones — all generic), obinutuzumab (Gazyva), tazemetostat (Tazverik — EZH2 inhibitor for EZH2-mutant or wild-type FL after 2+ prior systemic therapies), tafasitamab (Monjuvi) + lenalidomide (Revlimid generic available), Polivy (polatuzumab vedotin — DLBCL primarily but expanding), Columvi (glofitamab — CD20×CD3 bispecific for DLBCL), CAR-T cell therapy (axicabtagene/Yescarta, lisocabtagene/Breyanzi, tisagenlecleucel/Kymriah for FL per ZUMA-5/TRANSCEND FL/ELARA). Allogeneic SCT for select cases.
What is Lunsumio Prescription Assistance Program?
The Lunsumio Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Lunsumio (used for relapsed or refractory follicular lymphoma after at least two prior systemic therapies) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, hematology/oncology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing relapsed lymphoma.
At AffordMyPrescriptions, our Patient Advocates handle the entire Lunsumio PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your step-up dosing infusion schedule, and handle annual re-certification — so you never face a gap in your Lunsumio bispecific antibody therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Lunsumio enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your follicular lymphoma treatment.
Pharmacy Price Comparison
- Without assistance, Lunsumio costs thousands of dollars per dose at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted lymphoma therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Lunsumio advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Rituxan biosimilars + chemo (alt) | ~$3,500/cycle | Generic backbone alt |
| Hospital oncology | ~$15,500/dose | Save substantially |
| Community oncology | ~$13,500/dose | Save substantially |
| Specialty pharmacy | ~$12,500/dose | Save substantially |
| 340B-eligible institution | ~$12,000/dose | Save substantially |
| CAR-T cell therapy (alt) | ~$425,000 total | Alt cellular therapy — one-time |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Lunsumio — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Lunsumio Prescription Program?
The Lunsumio Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Lunsumio offers off-the-shelf alternative to CAR-T with shorter treatment duration (fixed 8 cycles for responders).
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Lunsumio assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Lunsumio is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Lunsumio:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $12,000–$16,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Lunsumio assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Lunsumio Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Lunsumio:
Lunsumio is a CD20 × CD3 bispecific T-cell engager — binds CD20 on B-cell lymphoma cells and CD3 on T cells, bringing them into proximity to redirect cytotoxic T-cell activity against tumor cells. Off-the-shelf alternative to CAR-T cell therapy. The pivotal GO29781 trial established efficacy in relapsed/refractory follicular lymphoma after 2+ prior systemic therapies. Fixed treatment duration (8 cycles for responders) — contrast to ongoing immunochemotherapy.
How It Works:
Follicular lymphoma (FL) is the most common indolent non-Hodgkin B-cell lymphoma — characteristically marked by BCL2 translocation and CD20 expression. Despite multiple effective therapies, FL is typically incurable with relapses occurring over years to decades; later lines have progressively shorter response durations. Mosunetuzumab is a humanized IgG1 bispecific antibody with one arm binding CD20 on B cells (tumor target) and the other arm binding CD3 on T cells. The bispecific engagement brings T cells into proximity with tumor cells, activates T cells, and triggers cytotoxic T cell-mediated tumor cell killing. Step-up dosing in cycle 1 mitigates cytokine release syndrome risk. Fixed treatment duration of 8 cycles for responders.
Form and Use:
Lunsumio IV infusion with step-up dosing in cycle 1 to mitigate cytokine release syndrome (CRS): cycle 1 day 1 (1 mg), day 8 (2 mg), day 15 (60 mg); cycle 2 day 1 (60 mg); cycles 3+ (30 mg every 21 days). Total 8 cycles for responders (or up to 17 cycles for delayed responses). Premedication for cycles with step-up dosing — corticosteroid, antihistamine, antipyretic. Monitor closely for CRS (especially first cycle), neurologic toxicity. CRS management: tocilizumab, corticosteroids. Tumor lysis syndrome prophylaxis (hydration, allopurinol). Periodic CBC, CMP.
Generic Availability:
No biosimilar/generic. Other CD20-targeting bispecific antibodies for B-cell lymphomas: epcoritamab (Epkinly — for DLBCL and FL), glofitamab (Columvi — for DLBCL primarily). Other FL therapies: rituximab (Rituxan with biosimilars now widely available substantially cheaper — Truxima, Ruxience, Riabni) ± chemotherapy (bendamustine + rituximab/BR; CHOP-rituximab — all generic chemo backbones); obinutuzumab (Gazyva — anti-CD20 mAb with biosimilars emerging); tazemetostat (Tazverik — EZH2 inhibitor for EZH2-mutant or wild-type FL after 2+ prior systemic therapies); tafasitamab (Monjuvi) + lenalidomide (Revlimid — generic available); CAR-T cell therapy (axicabtagene ciloleucel/Yescarta per ZUMA-5, lisocabtagene maraleucel/Breyanzi per TRANSCEND FL, tisagenlecleucel/Kymriah per ELARA) — one-time cellular therapy with significant logistics and toxicity considerations. Allogeneic SCT for select cases. Watch-and-wait for asymptomatic low-tumor-burden FL. Radiation for localized stage I/II FL.
Warnings:
Boxed warnings: cytokine release syndrome (CRS — common, especially with first doses; can be severe; step-up dosing mitigates; manage with tocilizumab and corticosteroids), neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS — less common than with CAR-T but reported; monitor; manage with corticosteroids), serious infections (bacterial, viral, fungal — including hepatitis B reactivation; screen and consider HBV prophylaxis), tumor lysis syndrome (high disease burden — hydration, allopurinol, monitor labs). Other: cytopenias (especially neutropenia, lymphopenia — prolonged depletion; consider G-CSF; monitor for infection), embryo-fetal toxicity, hypogammaglobulinemia (consider IVIG for recurrent infections), fatigue, pyrexia (often CRS-related), headache. Live vaccines avoided.
FAQ (Frequently Asked Questions)
How much does Lunsumio cost without insurance?
$12,000–$16,000 per dose. Total 8-cycle treatment course can cost $150,000–$200,000. Specialty pharmacy and Patient Assistance Programs are essential. Time-limited treatment course distinguishes from indefinite-duration therapies.
Is Lunsumio considered chemotherapy?
No — Lunsumio is a targeted immunotherapy (bispecific T-cell engager antibody) — recruits the patient’s own T cells to kill tumor cells. Different mechanism from cytotoxic chemotherapy with different toxicity profile, including immunotherapy-specific toxicities like CRS and ICANS.
What is the difference between Lunsumio and CAR-T cell therapy for follicular lymphoma?
Both target CD19 or CD20 on B-cell lymphoma using T cells. CAR-T (Yescarta, Breyanzi, Kymriah) requires harvesting patient T cells, genetically engineering them, and reinfusing — complex logistics, one-time infusion, ~$425,000+ cost, requires specialized centers, intensive monitoring for CRS/ICANS. Lunsumio is off-the-shelf bispecific antibody, step-up dosing then every-3-week infusion, 8 cycles for responders, treated at community oncology with appropriate CRS preparedness. Choice often by patient fitness, logistics, prior CAR-T eligibility/availability, and clinician preference.
What is cytokine release syndrome (CRS) and how is it managed?
CRS is immune activation with fever, hypotension, tachycardia, hypoxia, organ dysfunction — caused by T-cell activation releasing inflammatory cytokines. With Lunsumio, step-up dosing in cycle 1 mitigates CRS risk; most CRS is grade 1–2 and managed with supportive care. Severe CRS treated with tocilizumab (anti-IL-6R) and corticosteroids. Close monitoring during initial cycles is essential.
How long is Lunsumio treatment?
Fixed 8 cycles for responders (each cycle is 21 days = approximately 5–6 months total). Up to 17 cycles for delayed responses. Time-limited treatment is a major advantage over indefinite-duration therapies — completing treatment and returning to surveillance.
Take Control of Your Medication Costs
Targeted bispecific antibody therapy for relapsed/refractory follicular lymphoma should not be derailed by cost. Lunsumio offers time-limited treatment course as off-the-shelf alternative to CAR-T. Our Lunsumio advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Lunsumio through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.